Lower urinary tract symptoms and sexual dysfunction: A common approach

BJU International, Supplement

Volumn 101, Issue SUPPL. 3, 2008, Pages 22-26

  Giuliano, François ^a  

^a RAYMOND POINCARÉ HOSPITAL   (France)

Author keywords

1 blockers; Alfuzosin; Erectile dysfunction; Lower urinary tract symptoms; PDE 5 inhibitors; Tadalafil

Indexed keywords

ALFUZOSIN; ALPHA 1 ADRENERGIC RECEPTOR; ALPHA 1 ADRENERGIC RECEPTOR BLOCKING AGENT; DOXAZOSIN; FINASTERIDE; MOXISYLYTE; PHOSPHODIESTERASE V INHIBITOR; PLACEBO; SILDENAFIL; TADALAFIL; TAMSULOSIN; VARDENAFIL;

ANEJACULATION; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CORPUS CAVERNOSUM; DETRUSOR MUSCLE; DRUG DOSE INCREASE; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; DRUG TOLERABILITY; EJACULATION DISORDER; ERECTILE DYSFUNCTION; HUMAN; HYPOTENSION; LOWER URINARY TRACT SYMPTOM; MONOTHERAPY; PRIORITY JOURNAL; PROSTATE HYPERTROPHY; REVIEW; SEXUAL DYSFUNCTION; SINGLE DRUG DOSE; SYNCOPE;

ADRENERGIC ALPHA-ANTAGONISTS; DRUG THERAPY, COMBINATION; HUMANS; IMPOTENCE, VASCULOGENIC; MALE; PHOSPHODIESTERASE INHIBITORS; PROSTATIC HYPERPLASIA; PROSTATISM; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RETROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 40149105274     PISSN: 14655101     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1464-410X.2008.07494.x     Document Type: Review

References (31)

1. Braun M, Wassmer G, Klotz T, Reifenrath B, Mathers M, Engelmann U. Epidemiology of erectile dysfunction: results of the 'Cologne male survey Int J Impot Res 2000 12 : 305 11
2. Rosen R, Altwein J, Boyle P et al. Lower urinary tract symptoms and male sexual dysfunction: the multinational survey of the aging male (MSAM-7). Eur Urol 2003 44 : 637 49
3. Vallancien G, Emberton M, Harving N et al. Sexual dysfunction in 1274 European men suffering from lower urinary tract symptoms. J Urol 2003 169 : 2257 61
4. Li MK, Garcia LA, Rosen R. Lower urinary tract symptoms and male sexual dysfunction in Asia: a survey of aging men from 5 Asian countries. BJU Int 2005 96 : 1339 54
5. McVary K. Lower urinary tract symptoms and sexual dysfunction: epidemiology and pathophysiology. BJU Int 2006 97 (Suppl. 2 23 8
6. American Urological Association (AUA) Practice Guidelines Committee. AUA Guideline on Management of Benign Prostatic Hyperplasia (2003). Chapter 1: diagnosis and treatment recommendations. J Urol 2003 170 : 530 47
7. Lue TF, Guiliano F, Montorsi F et al. Summary of the recommendations on sexual dysfunctions in men. J Sex Med 2004 1 : 6 23
8. Carson CC. Combination of phosphodiesterase-5 inhibitors and alpha-blockers in patients with benign prostatic hyperplasia: treatments of lower urinary tract symptoms, erectile dysfunction, or both? BJU Int 2006 97 (Suppl. 2 39 43
9. Kloner RA, Jackson G, Emmick JT, et al. Interaction between the phosphodiesterase 5 inhibitor tadalafil and 2 alpha-blockers, doxazosin and tamsulosin in healthy normotensive men. J Urol 2004 172 : 1935 40
10. 1-blocker alfuzosin and the phosphodiesterase-5 inhibitor tadalafil in middle-aged healthy male subjects. Urology 2006 67 : 1199 204
11. van Kerrebroeck P, Jardin A, Laval KU, van Cangh P. Efficacy and safety of a new prolonged release formulation of alfuzosin 10 mg once daily versus alfuzosin 2.5 mg thrice daily and placebo in patients with symptomatic benign prostatic hyperplasia. ALFORTI Study Group. Eur Urol 2000 37 : 306 13
12. Roehrborn CG. Efficacy and safety of once-daily alfuzosin in the treatment of lower urinary tract symptoms and clinical benign prostatic hyperplasia: a randomized, placebo-controlled trial. Urology 2001 58 : 953 9
13. Roehrborn CG, Van Kerrebroeck P, Nordling J. Safety and efficacy of alfuzosin 10 mg once-daily in the treatment of lower urinary tract symptoms and clinical benign prostatic hyperplasia: a pooled analysis of three double-blind, placebo-controlled studies. BJU Int 2003 92 : 257 61
14. Lepor H. Long-term evaluation of tamsulosin in benign prostatic hyperplasia: placebo-controlled, double-blind extension of phase III trial. Tamsulosin Investigator Group. Urology 1998 51 : 901 6
15. Hellstrom WJG, Sikka SC. Effects of acute treatment with tamsulosin versus alfuzosin on ejaculatory function in healthy volunteers. J Urol 2006 76 : 1529 33
16. Andersson KE, Wyllie MG. Ejaculatory dysfunction: why all alpha-blockers are not equal. BJU Int 2003 92 : 876 7
17. 2-like receptors mediate the expulsion phase of ejaculation elicited by 8-hydroxy-2-(di-N-propylamino) tetralin in rats. J Pharmacol Exp Ther 2006 316 : 830 4
18. Giuliano F, Bernabé J, Denys P et al. Comparison between tamsulosin and alfuzosin on the expulsion phase of ejaculation in rats. BJU Int 2006 98 : 876 9
19. Lue TF. Erectile dysfunction. N Engl J Med 2000 342 : 1802 13
20. Palea S, Barras M. Comparison of the relaxant effects of alfuzosin, phentolamine and sildenafil on rabbit isolated corpus cavernosum. BJU Int 2003 91 : 873 7
21. Kirby RS, O'Leary MP, Carson C. Efficacy of extended-release doxazosin and doxazosin standard in patients with concomitant benign prostatic hyperplasia and sexual dysfunction. BJU Int 2005 95 : 103 9
22. Vallancien G, Emberton M, Alcaraz A et al. Alfuzosin 10 mg once daily for treating benign prostatic hyperplasia: a 3-year experience in real-life practice. BJU Int 2008 (in press)
23. McVary KT, Monnig W, Camps JL Jr., Young JM, Tseng L J, van den Ende G. Sildenafil citrate improves erectile function and urinary symptoms in men with erectile dysfunction and lower urinary tract symptoms associated with benign prostatic hyperplasia: a randomized, double-blind trial. J Urol 2007 177 : 1071 7
24. McVary KT, Roehrborn CG, Kaminetsky JC et al. Tadalafil relieves lower urinary tract symptoms secondary to benign prostatic hyperplasia. J Urol 2007 177 : 1401 7
25. Stief CG, Porst H, Evers T, Ulbrich E. Vardenafil in the treatment of symptomatic benign prostatic hyperplasia. J Urol 2007 177 (Suppl. 517 Abstract 1565)
26. Gacci M, Del Popolo G, Macchiarella A et al. Vardenafil improves urodynamic parameters in men with spinal cord injury: results from a single dose, pilot study. J Urol 2007 178 : 2040 3 discussion 2044
27. Oger-Roussel S, Behr-Roussel D, Gorny D et al. Combination of alfuzosin and tadalafil exerts in vitro an additive relaxant effect on human corpus cavernosum. J Sex Med 2008 (in press)
28. Oger S, Behr-Roussel D, Gorny D et al. Combination of alfuzosin and tadalafil exerts additive relaxant effect on human prostate. Urology 2007 70 (Suppl. 1 109 (Abstract 347)
29. Oger S, Behr-Roussel D, Lecoz O et al. Combination of alfuzosin and tadalafil exerts an additive enhancing effect on norepinephrine-induced relaxation of pre-contracted human detrusor smooth muscle. Urology 2007 70 (Suppl. 1 154 (Abstract 491)
30. Yassin A, Diede H-E. Combination therapy: alpha1-adrenoceptor blockade and tadalafil in BPH population. In J Impot Res 2003 15 (Suppl. 6 2 5
31. Kaplan S, Gonzalez RR, Te AE. Combination of alfuzosin and sildenafil is superior to monotherapy in treating lower urinary tract symptoms and erectile dysfunction. Eur Urol 2007 51 : 1717 23